B+
Bull case
20%
Probability
Target price
$60.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
XENE
XenonDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The submitted focal-seizure application preserves a potential first-launch pathway, while a tolerable dosing approach and positive X-NOVA2 data could restore some psychiatry optionality. Xenon reported $1.2 billion in cash and marketable securities at Q2 and projected runway into 2029.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -3.8.
What can break
FDA review timing, approval, labeling, and eventual epilepsy uptake remain uncertain.
Momentum
4
Value
41
Sentiment
59
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $38.00 · Bull $60.00 · Bear $20.00Analysis 2026-09-26; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-26 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $71.94
Why
Momentum4 · Δ7d +1.4
Value41 · Δ7d -0.1
Sentiment59 · Δ7d -3.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -3.8.
Contradictions & invalidation
- • FDA review timing, approval, labeling, and eventual epilepsy uptake remain uncertain.
- • Multiple trials and launch preparation can increase spending; the reported runway is a company projection, not a guarantee. [#SEC-8K-2026-08-06]
- • The safety-related enrollment pause could delay or diminish the depression opportunity.
Catalyst clock
2026-12-31
Psychiatry-study safety review
Lead driver: Sentiment · See AI snapshot
Momentum
4
8% active weight
Current posture
7d trendImproving
Δ7d
+1.4
Δ21d
+1.1
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
59
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.8
Δ21d
-3.5
Why this grade
Composite grade D. Momentum 4.0 / Value 40.6 / Sentiment 59.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-26. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$38.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$20.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$3.49B
Beta
0.96
Shares Out
96.84M
P/E (TTM) · Derived
-8.3
P/S (TTM)
430.58
P/FCF (TTM) · Derived
-9.28
Rev YoY
-100.0%
EPS YoY
+3.6%
Gross Margin
+66.1%
Op Margin
-4543.7%
Net Debt
-$540.94M
Current Ratio
21.02
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data